IR Iran
Case Report
Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with
Checkpoint Inhibitors: A Case Report
Author(s): Xizhi Wen, Ya Ding, Baoyan Zhu, Dandan Li, Jinjin Li, Yao Wang and Xiaoshi ZhangXizhi Wen, Ya Ding, Baoyan Zhu, Dandan Li, Jinjin Li, Yao Wang and Xiaoshi Zhang
Based on remarkable and sustained antitumor activity, the anti-CTLA-4 antibody ipilimumab, and anti-PD1 antibodies nivolumab and pembrolizumab have been approved for treatment of advanced melanoma. As checkpoint blockade is associated with potentially serious immune-related adverse events, including autoimmune hepatitis, clinical trials evaluating these agents have excluded patients with chronic hepatitis B virus infection. Herein, we describe one patient with advanced melanoma and concomitant HBV infections experiencing seroconversion of HBsAg after treatment with combination of PD-1 and CTLA-4 blockade.
.. Read More»
DOI:
10.4172/2165-7920.1000951
Journal of Clinical Case Reports received 1295 citations as per Google Scholar report